186 related articles for article (PubMed ID: 24652192)
21. Loss of PTEN is not associated with poor survival in newly diagnosed glioblastoma patients of the temozolomide era.
Carico C; Nuño M; Mukherjee D; Elramsisy A; Dantis J; Hu J; Rudnick J; Yu JS; Black KL; Bannykh SI; Patil CG
PLoS One; 2012; 7(3):e33684. PubMed ID: 22479427
[TBL] [Abstract][Full Text] [Related]
22. The impact of MGMT methylation and IDH-1 mutation on long-term outcome for glioblastoma treated with chemoradiotherapy.
Millward CP; Brodbelt AR; Haylock B; Zakaria R; Baborie A; Crooks D; Husband D; Shenoy A; Wong H; Jenkinson MD
Acta Neurochir (Wien); 2016 Oct; 158(10):1943-53. PubMed ID: 27526690
[TBL] [Abstract][Full Text] [Related]
23. Survival benefit of levetiracetam in patients treated with concomitant chemoradiotherapy and adjuvant chemotherapy with temozolomide for glioblastoma multiforme.
Kim YH; Kim T; Joo JD; Han JH; Kim YJ; Kim IA; Yun CH; Kim CY
Cancer; 2015 Sep; 121(17):2926-32. PubMed ID: 25975354
[TBL] [Abstract][Full Text] [Related]
24. High levels of phosphorylated MAP kinase are associated with poor survival among patients with glioblastoma during the temozolomide era.
Patil CG; Nuño M; Elramsisy A; Mukherjee D; Carico C; Dantis J; Hu J; Yu JS; Fan X; Black KL; Bannykh SI
Neuro Oncol; 2013 Jan; 15(1):104-11. PubMed ID: 23115159
[TBL] [Abstract][Full Text] [Related]
25. DARPP32, STAT5 and STAT3 mRNA expression ratios in glioblastomas are associated with patient outcome.
Televantou D; Karkavelas G; Hytiroglou P; Lampaki S; Iliadis G; Selviaridis P; Polyzoidis KS; Fountzilas G; Kotoula V
Pathol Oncol Res; 2013 Apr; 19(2):329-43. PubMed ID: 23250732
[TBL] [Abstract][Full Text] [Related]
26. Karnofsky performance status predicts overall survival, cancer-specific survival, and progression-free survival following radical cystectomy for urothelial carcinoma.
Evers PD; Logan JE; Sills V; Chin AI
World J Urol; 2014 Apr; 32(2):385-91. PubMed ID: 23756991
[TBL] [Abstract][Full Text] [Related]
27. The role of p-Stat3 Y705 immunohistochemistry in glioblastoma prognosis.
Susman S; Pîrlog R; Leucuța D; Mitre AO; Padurean VA; Melincovici C; Moldovan I; Crișan D; Florian SI
Diagn Pathol; 2019 Nov; 14(1):124. PubMed ID: 31690341
[TBL] [Abstract][Full Text] [Related]
28. Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme.
Prados MD; Wara WM; Sneed PK; McDermott M; Chang SM; Rabbitt J; Page M; Malec M; Davis RL; Gutin PH; Lamborn K; Wilson CB; Phillips TL; Larson DA
Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):71-7. PubMed ID: 11163499
[TBL] [Abstract][Full Text] [Related]
29. Clinical features associated with the efficacy of chemotherapy in patients with glioblastoma (GBM): a surveillance, epidemiology, and end results (SEER) analysis.
Wen J; Chen W; Zhu Y; Zhang P
BMC Cancer; 2021 Jan; 21(1):81. PubMed ID: 33468109
[TBL] [Abstract][Full Text] [Related]
30. Bioinformatic analyses reveal a distinct Notch activation induced by STAT3 phosphorylation in the mesenchymal subtype of glioblastoma.
Cheng W; Zhang C; Ren X; Jiang Y; Han S; Liu Y; Cai J; Li M; Wang K; Liu Y; Hu H; Li Q; Yang P; Bao Z; Wu A
J Neurosurg; 2017 Jan; 126(1):249-259. PubMed ID: 26967788
[TBL] [Abstract][Full Text] [Related]
31. Pre-Operative Perfusion Skewness and Kurtosis Are Potential Predictors of Progression-Free Survival after Partial Resection of Newly Diagnosed Glioblastoma.
Paik W; Kim HS; Choi CG; Kim SJ
Korean J Radiol; 2016; 17(1):117-26. PubMed ID: 26798224
[TBL] [Abstract][Full Text] [Related]
32. Impact of removed tumor volume and location on patient outcome in glioblastoma.
Awad AW; Karsy M; Sanai N; Spetzler R; Zhang Y; Xu Y; Mahan MA
J Neurooncol; 2017 Oct; 135(1):161-171. PubMed ID: 28685405
[TBL] [Abstract][Full Text] [Related]
33. Prognosis of cerebellar glioblastomas: correlation between prognosis and immunoreactivity for epidermal growth factor receptor compared with supratentorial glioblastomas.
Saito T; Hama S; Kajiwara Y; Sugiyama K; Yamasaki F; Arifin MT; Arita K; Kurisu K
Anticancer Res; 2006; 26(2B):1351-7. PubMed ID: 16619544
[TBL] [Abstract][Full Text] [Related]
34. Multi-institutional external validation of a novel glioblastoma prognostic nomogram incorporating MGMT methylation.
Molitoris JK; Rao YJ; Patel RA; Kane LT; Badiyan SN; Gittleman H; Barnholtz-Sloan JS; Bentzen SM; Kruser TJ; Huang J; Mehta MP
J Neurooncol; 2017 Sep; 134(2):331-338. PubMed ID: 28643151
[TBL] [Abstract][Full Text] [Related]
35. Gross total but not incomplete resection of glioblastoma prolongs survival in the era of radiochemotherapy.
Kreth FW; Thon N; Simon M; Westphal M; Schackert G; Nikkhah G; Hentschel B; Reifenberger G; Pietsch T; Weller M; Tonn JC;
Ann Oncol; 2013 Dec; 24(12):3117-23. PubMed ID: 24130262
[TBL] [Abstract][Full Text] [Related]
36. Impact of oligodendroglial component in glioblastoma (GBM-O): Is the outcome favourable than glioblastoma?
Goda JS; Lewis S; Agarwal A; Epari S; Churi S; Padmavati A; Gupta T; Shetty P; Moiyadi A; Jalali R
Clin Neurol Neurosurg; 2015 Aug; 135():46-53. PubMed ID: 26038275
[TBL] [Abstract][Full Text] [Related]
37. Effect of the JAK2/STAT3 inhibitor SAR317461 on human glioblastoma tumorspheres.
Mukthavaram R; Ouyang X; Saklecha R; Jiang P; Nomura N; Pingle SC; Guo F; Makale M; Kesari S
J Transl Med; 2015 Aug; 13():269. PubMed ID: 26283544
[TBL] [Abstract][Full Text] [Related]
38. Influence of wide opening of the lateral ventricle on survival for supratentorial glioblastoma patients with radiotherapy and concomitant temozolomide-based chemotherapy.
Saito T; Muragaki Y; Maruyama T; Komori T; Nitta M; Tsuzuki S; Fukui A; Kawamata T
Neurosurg Rev; 2020 Dec; 43(6):1583-1593. PubMed ID: 31705405
[TBL] [Abstract][Full Text] [Related]
39. Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial.
Gállego Pérez-Larraya J; Ducray F; Chinot O; Catry-Thomas I; Taillandier L; Guillamo JS; Campello C; Monjour A; Cartalat-Carel S; Barrie M; Huchet A; Beauchesne P; Matta M; Mokhtari K; Tanguy ML; Honnorat J; Delattre JY
J Clin Oncol; 2011 Aug; 29(22):3050-5. PubMed ID: 21709196
[TBL] [Abstract][Full Text] [Related]
40. Prognostic factors influencing clinical outcomes of glioblastoma multiforme.
Li SW; Qiu XG; Chen BS; Zhang W; Ren H; Wang ZC; Jiang T
Chin Med J (Engl); 2009 Jun; 122(11):1245-9. PubMed ID: 19567131
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
